{"entity":{"id":"nct07095868","kind":"trial","name":"Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Everest Medicines (Beijing) Co., Ltd., now recruiting.","summary":"Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors is a phase 1/2 interventional study registered as NCT07095868 by Everest Medicines (Beijing) Co., Ltd., with 94 participants planned, started 2025-11-17 and due to reach its primary completion in 2029-11. Interventions recorded: EVM14 and Pembrolizumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07095868","url":"https://clinicaltrials.gov/study/NCT07095868"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07095868","phase":"1/2","setting":"A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Solid Tumors","sponsor":"Everest Medicines (Beijing) Co., Ltd.","enrolled":94,"outcomes":[]},"route":"/trials/nct07095868/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"evm14","kind":"drug","name":"EVM14","route":"/drugs/evm14/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}